Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
crispr
4
×
deals
4
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
startups
4
×
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
biogen
clinical trials
editas medicine
eli lilly
fda
generic drugs
What
bio
roundup
develop
new
acquisitions
announced
approval
available
bails
based
big
biogen’s
biopharmaceutical
biosciences
brand
bridgebio
capital
car
cas
ceo
cheaper
collabs
companies
convo
covid
crispr
daniel
deal
diagnostics
drug
drugs
earlier
emerges
expects
failures
faster
firm
gilead
gilead’s
grab
Language
unset
Current search:
crispr
×
biotech
×
startups
×
deals
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More